Posted by Michael Wonder on 02 Aug 2024
Health Canada approves Celltrion’s Steqeyma, a biosimilar to Stelara (ustekinumab) for the treatment of multiple chronic inflammatory conditions
1 August 2024 - Steqeyma, is now approved in Canada for adult patients with plaque psoriasis as well as adults with active psoriatic arthritis and Crohn’s disease.
Celltrion Healthcare Canada today announced that Health Canada has approved Steqeyma (ustekinumab injection) and Steqeyma I.V. (ustekinumab for injection, solution for intravenous infusion) for the treatment of moderately to severely active Crohn’s disease in adults, moderate to severe plaque psoriasis in adult patients, and active psoriatic arthritis.
